Eli Lilly stock is back near the $1,000 mark, and the move is drawing fresh attention from investors who are trying to decide whether the recent pullback was a pause or the start of something bigger. The shares edged up 0.43% to $987.53 in the latest session, a modest gain on the surface, but one that stood out because it arrived while the broader market and healthcare sector were both under pressure.
That relative strength matters. Lilly has still fallen about 3.7% since its last earnings report and is down roughly 5.2% over the past month, but the company’s underlying numbers continue to tell a very different story. Fourth-quarter earnings and revenue both beat expectations, blockbuster obesity and diabetes drugs kept expanding at a stunning pace, and management laid out a 2026 growth outlook that remains among the strongest in large-cap pharma.
Key data points at a glance: LLY closed near $987.53, Q4 adjusted EPS came in at $7.54 versus expectations of $6.99, revenue reached $19.3 billion versus expectations of $17.87 billion, and the company expects $80 billion to $83 billion in 2026 revenue with EPS projected at $33.50 to $35.00.
Earnings strength is still the central story
Lilly’s latest quarter was difficult to ignore. Adjusted earnings per share rose 42% year over year to $7.54, while revenue surged 43% to $19.3 billion. Both figures came in ahead of Wall Street expectations, reinforcing the view that the company remains one of the most powerful growth stories in the healthcare sector.
The biggest driver was the same one investors have been watching for months: extraordinary demand for Mounjaro and Zepbound. Those two products continue to reshape Lilly’s revenue mix and have become the main reason the market remains willing to value the stock at premium levels even after its massive run.
For full-year 2025, the company delivered sales of $65.2 billion, up 45% from the prior year. Adjusted earnings for the year climbed 86% to $24.21 per share. Those are not the numbers of a company losing momentum. They are the numbers of a company still operating in the heart of a major demand cycle.
Mounjaro and Zepbound are doing the heavy lifting
Mounjaro posted quarterly sales of $7.41 billion, up 110% year over year. In the United States, sales rose to $4.1 billion, while international revenue reached $3.3 billion as Lilly expanded into more markets. The product has established itself as the market leader in type 2 diabetes incretin analogs, with Lilly saying it captured 55% of new prescriptions in that category.
Zepbound was just as impressive. The obesity drug generated $4.26 billion in quarterly revenue, up 123% from a year earlier. Lilly said Zepbound captured 70% of new prescriptions in the quarter, underlining how dominant the launch has been in one of the fastest-growing segments in global medicine.
Those two medicines are not the whole story, but they are clearly the core of it. Investors looking for proof of Lilly’s staying power will keep returning to these products because they are driving both current growth and expectations for 2026. The company’s broader lineup of newer products also remains meaningful, with key new therapies contributing more than $13 billion in fourth-quarter revenue, up 91% year over year.
Other products show a more mixed picture
Outside the flagship growth engines, the portfolio looks more uneven. Trulicity revenue fell 17% to $1.04 billion as patients shifted toward Mounjaro and pricing stayed under pressure. Jardiance sales dropped 36% to $768 million. Those declines show the trade-off inside Lilly’s own portfolio, where new winners are increasingly displacing older franchises.
Elsewhere, Taltz brought in $1.05 billion, up 10%, while Verzenio generated $1.60 billion, up 3%. Lilly also continued to build newer categories, including Alzheimer’s treatment Kisunla, which delivered $109 million in sales in the quarter, up from the prior quarter as awareness and diagnosis improved.
The mix matters because it helps explain both the upside and the caution around the stock. Lilly has blockbuster momentum, but it also has product transitions, price pressure, and a need to keep replenishing growth beyond today’s leaders.
2026 guidance keeps the bull case alive
The most important part of the report may have been management’s forward outlook. Lilly expects 2026 revenue in the range of $80 billion to $83 billion, representing about 25% growth at the midpoint. Earnings per share are projected at $33.50 to $35.00, a range that suggests another year of sharp expansion even after an already explosive 2025.
The company also expects continued growth from Mounjaro and Zepbound, while newer products such as Ebglyss, Jaypirca, Inluriyo, Kisunla and Omvoh add to the top line. One future catalyst investors will be watching closely is orforglipron, Lilly’s oral obesity treatment, which the company expects to launch in the United States in the second quarter of 2026. That gives Lilly another potential lever in a market already rewarding convenience and scale.
For investors who want to examine the company’s latest outlook directly, Lilly’s 2026 guidance and investor updates remain central to the stock’s premium valuation.
The risks have not disappeared
Even with those numbers, the stock has not moved in a straight line. The recent decline since earnings suggests investors are weighing real concerns. Pricing pressure is one. Lilly said net realized prices declined 5% in the quarter even as volumes rose 46%. Competition is another. The obesity and diabetes markets are attracting more rivals, and the stakes in those categories are only getting larger.
Costs are also moving up. Research and development expense rose 26% to $3.8 billion, while marketing, selling and administrative expenses increased 29% to $3.1 billion. That spending reflects confidence in the pipeline and global expansion plans, but it also means Lilly has to keep delivering exceptional revenue growth to preserve margin strength.
There was also some recent insider transaction activity, though nothing in the reported figures suggested unusual selling pressure. The disclosed transactions between February 17 and 19 totaled $43,209.50 and mostly consisted of stock awards, with one stock gift included in the filings.
The market takeaway: Lilly’s stock may have slipped in the weeks after earnings, but the business itself is still producing elite growth. With revenue up 43% in the quarter, full-year sales at $65.2 billion, and 2026 guidance pointing to as much as $83 billion in revenue, the path higher remains intact as long as Mounjaro and Zepbound keep leading the category.
That leaves investors with a simple but important debate. At nearly $1,000 a share, Lilly is no longer a hidden story. But in a market still searching for durable earnings growth, it remains one of the few healthcare names delivering the kind of scale, speed and product momentum that can justify a premium. The latest price action may look modest. The fundamentals behind it do not.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
